A detailed history of Silvercrest Asset Management Group LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 111,706 shares of BMY stock, worth $6.45 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
111,706
Previous 112,295 0.52%
Holding current value
$6.45 Million
Previous $4.66 Million 23.95%
% of portfolio
0.04%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $23,359 - $30,480
-589 Reduced 0.52%
111,706 $5.78 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $4.52 Million - $5.95 Million
-112,295 Reduced 50.0%
112,295 $4.66 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $4.54 Million - $5.98 Million
112,820 Added 100.94%
224,590 $9.33 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $18,568 - $21,052
-387 Reduced 0.35%
111,770 $6.06 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $51,146 - $61,031
-1,055 Reduced 0.93%
112,157 $5.75 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $810 - $906
14 Added 0.01%
113,212 $6.57 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $764 - $848
12 Added 0.01%
113,198 $7.24 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $48,559 - $55,077
-739 Reduced 0.65%
113,186 $7.84 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $81,696 - $96,740
1,193 Added 1.06%
113,925 $8.2 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $26 - $15,368
-200 Reduced 0.18%
112,732 $8.01 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $223,379 - $246,018
-3,076 Reduced 2.65%
112,932 $8.7 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $246,596 - $295,690
-4,011 Reduced 3.34%
116,008 $8.47 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $1.39 Million - $1.62 Million
-25,833 Reduced 17.71%
120,019 $7.48 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $732,169 - $857,641
-12,374 Reduced 7.82%
145,852 $8.63 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $2,476 - $2,696
40 Added 0.03%
158,226 $10.6 Million
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $1.02 Million - $1.15 Million
-17,252 Reduced 9.83%
158,186 $9.99 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $167,330 - $189,616
-2,898 Reduced 1.63%
175,438 $10.9 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $20,904 - $23,164
-364 Reduced 0.2%
178,336 $10.8 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $406,106 - $474,778
-7,408 Reduced 3.98%
178,700 $10.5 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $342,756 - $498,105
-7,387 Reduced 3.82%
186,108 $10.4 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $1.34 Million - $1.75 Million
27,287 Added 16.42%
193,495 $12.4 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $43,197 - $51,217
1,010 Added 0.61%
166,208 $8.43 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $14,501 - $16,035
-325 Reduced 0.2%
165,198 $7.49 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $105,039 - $125,246
2,328 Added 1.43%
165,523 $7.9 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $24,380 - $31,615
-500 Reduced 0.31%
163,195 $8.48 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $351,505 - $396,470
-6,369 Reduced 3.75%
163,695 $10.2 Million
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $306,969 - $382,603
-6,075 Reduced 3.45%
170,064 $9.41 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $500,332 - $575,983
-8,350 Reduced 4.53%
176,139 $11.1 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $481,318 - $524,760
8,030 Added 4.55%
184,489 $11.3 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $9.75 Million - $11.2 Million
176,459
176,459 $11.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.